Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2116885 | Cancer Letters | 2007 | 8 Pages |
Abstract
Pre-treatment with high-dose 1α,25-dihydroxyvitamin D3 (1,25-VD) enhanced the antitumor activity of docetaxel in the androgen-independent prostate cancer cell line, PC-3. The effect manifested as an increasing population of apoptotic cells and amount of pro-apoptotic protein, Bax, under combined treatment compared with single treatment of either 1,25-VD or docetaxel alone. We further demonstrated that pre-treatment with 1,25-VD reduced the expression of multidrug resistance-associated protein-1 at both the mRNA and protein levels. This suggests pre-treatment with 1,25-VD can potentiate cytotoxicity of docetaxel in PC-3 due to 1,25-VD reducing multidrug resistance-associated protein-1 expression.
Keywords
HRPCVDRPGPPSAMRPEtOH1α,25-dihydroxyvitamin D33-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromideMTTP-glycoproteinPCAQuantitative PCRq-PCRProstate specific antigenEthanolDocetaxelProstate cancerHormone refractory prostate cancergrowth inhibitionmultidrug resistance-associated proteinMultidrug resistance proteinsVitamin D receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Huei-Ju Ting, Jeffery Hsu, Bo-Yin Bao, Yi-Fen Lee,